Irl B Hirsch,Desmond A Schatz
Irl B Hirsch
Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies [0.03%]
多胰岛自身抗体儿童的糖代谢异常定义及临床1型糖尿病发病进展关系
Sandra Hummel,Melanie Koeger,Ezio Bonifacio et al.
Sandra Hummel et al.
Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries [0.03%]
超过10万例1型糖尿病儿童的治疗方案及血糖结局（2013-2022年）：来自儿科糖尿病登记的数据纵向分析
Anthony T Zimmermann,Stefanie Lanzinger,Siv Janne Kummernes et al.
Anthony T Zimmermann et al.
Background: Advances in paediatric type 1 diabetes management and increased use of diabetes technology have led to improvements in glycaemia, reduced risk of severe hypoglycaemia, and improved quality of life. Since 1993,...
Correction to Lancet Diabetes Endocrinol 2024; published online Nov 12. https://doi.org/10.1016/S2213-8587(24)00283-3 [0.03%]
柳叶刀糖尿病内分泌学2024年在线发表修正版https://doi.org/10.1016/S2213-8587(24)00283-3
Published Erratum
The lancet. Diabetes & endocrinology. 2025 Jan;13(1):e1. DOI:10.1016/S2213-8587(24)00368-1 2025
Laura M Jacobsen,Mark A Atkinson,Jay M Sosenko et al.
Laura M Jacobsen et al.
In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 diabetes. This model, based on islet autoantibodies (stage 1) and dysglycaemia (stage 2) before type 1 diabetes diagnosis ...
Medications for obesity as preventatives: a public and patient safety issue [0.03%]
肥胖症药物的预防作用——一个公共和患者安全问题
Stuart W Flint,Adrian Brown,Verónica Vázquez-Velázquez et al.
Stuart W Flint et al.
Priya Sumithran,Jamy Ard
Priya Sumithran
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials [0.03%]
葡萄糖依赖的促胰岛素多肽受体激动剂对肾脏和心血管疾病结局影响的meta分析研究
Sunil V Badve,Anika Bilal,Matthew M Y Lee et al.
Sunil V Badve et al.
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes re...
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial [0.03%]
低风险甲状腺癌患者未经放射性碘治疗的甲状腺切除术：ESTIMABL2前瞻性随机试验的5年随访结果
Sophie Leboulleux,Claire Bournaud,Cecile N Chougnet et al.
Sophie Leboulleux et al.
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph...